Description
CJC 1295 + IPA combines a GHRH analogue with Ipamorelin, a growth hormone secretagogue. Researchers use this pairing to study two complementary GH-related pathways: one associated with GH signalling support and one associated with release-pulse signalling.
Molecular Profile
Molecular Weight: Refer to batch COA
Purity: Per batch COA
Format: Lyophilized white powder
Storage: -20°C, desiccated
Reconstitution: Sterile bacteriostatic water
Research Context
CJC 1295 + IPA is studied in endocrine research involving combined GHRH analogue and growth hormone secretagogue signalling. Research teams use combination preparations to evaluate complementary receptor pathways involved in pulsatile GH release and downstream IGF-1 models.
Quality Assurance
Each batch is independently tested for purity, identity, and quality before release. A Certificate of Analysis is available for every lot. All compounds are produced under strict quality control conditions and shipped under appropriate handling protocols from within Canada.
Reviews
There are no reviews yet.